HTDS-News Out

[rob111]

HARD TO TREAT DISEASES (HTDS) Granted Registration And Licensing Approval By Vietnam (FDA)


--SHENZEN,

SHENZEN, CHINA, March 25, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (HTDS) today after the market closed announced that Mellow Hope a subsidiary of HTDS was granted Registration And Licensing Approval By Vietnam Food and Drug Administration (FDA).
Following an eighteen-month unrelenting effort, the company was approved, registered, and licensed with the Vietnam FDA. This license permits Mellow Hope to go directly to the registration of other biological products (with the exception of Hepatitis A Vaccine); a great time-saving vehicle. Two-hundred and fifty vials are scheduled for delivery to Vietnam by the end of March 2009.

Mr Terry Yian CEO of HTDS said "The Hepatitis A Vaccine (H2 Strain, Brand Name: Mevac-A) is a self-owned product in China, with one dose carrying a life-long potency. One-hundred-sixty billion people have received this vaccination over the past fifteen years without any adverse side effects reported to date. The Vietnam population is at considerably high-risk for Hepatitis A. Current market demand is one-million doses, and far exceeds the supply. Once released, the local population will greatly benefit from Mevac-A's superior quality, and a highly competitive price".

CONTACT: For scientific dialogue and inquiry only, contact Andrea Zecevic Independent Consultant to the Company via e-mail at ; For any corporate matters, readers should contact the company directly at

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT:

SOURCE Hard to Treat Diseases